Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the UK and Ireland
LONDON--(BUSINESS WIRE)--Oct 1, 2018--Mawdsleys and Oncoscience GmbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher ® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181001005630/en/
Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of cancers. These approvals have been granted for the following indications: locally advanced or metastatic pancreatic cancer (adenocarcinoma), nasopharyngeal carcinoma, oesophageal cancer, lung cancer, high-malignant glial cancers (glioblastoma multiforme and anaplastic astrocytoma) and head & neck cancers in advanced stages. Nimotuzumab has also been approved in a number of countries for high-grade gliomas in children and adolescents (newly diagnosed, recurrent and refractory).
The EMEA granted orphan drug designation status for Nimotuzumab for the indications of glioma in 2004 and pancreatic cancer in 2008. Nimotuzumab has also received the US FDA orphan drug designation status for both indications.
The Named Patient Program for the UK and Ireland, which will be managed by Mawdsleys, will allow physicians access to CIMAher ® for patients who meet pre-specified medical criteria. Mawdsleys’ Director of Specialty Pharma, David Regan, comments “ We are pleased to be working with Oncoscience to create access to CIMAher®for patients in the UK and Ireland and so help address a current unmet medical need in the treatment of certain advanced cancers”.
Healthcare professionals can obtain further details about the Nimotuzumab Named Patient Program using the contact details below.
NOTES TO EDITORS
About CIMAher ® (Nimotuzumab)
Nimotuzumab is a humanized monoclonal antibody (mAb) that targets the epidermal growth factor receptor (EGFR). To date Nimotuzumab has been administered to more than 65,000 patients globally and is approved in 25 countries for multiple cancer types. Nimotuzumab is a well investigated mAb for treatment of tumours of epithelial origin as it has been published in more than 130 scientific peer review journals and involved in 92 clinical studies around the world.
Founded in 1825, Mawdsleys is a privately-owned pharmaceutical services company based in the UK with operations in Brazil and Israel. We deliver a wide range of services to both the pharmaceutical industry and healthcare sector through our main business areas which include: Named Patient Medicines (delivering global named patient programmes), Product Licensing and Market Access (In the EU, LATAM and Middle East regions), UK Wholesale (largest independent wholesaler to UK hospitals), UK Pre-wholesale (3PL and 4PL services in the UK), LUTO (healthcare communications) and Positive Solutions (pharmacy IT systems).
About Oncoscience GmbH
Oncoscience is a Germany based privately-owned biopharmaceutical company founded in 2001 to advance the development of novel products for the treatment of orphan indications in oncology. Oncoscience has the exclusive rights for the anti-EGFR monoclonal antibody Nimotuzumab, in the European Union and the surrounding area (in total 46 countries). Oncoscience is committed to further developing Nimotuzumab in Europe to address oncological diseases for which the unmet medical need is high and for which effective and safe therapy is urgently needed.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181001005630/en/
Mike Rawlings, Head of Commercial Operations
T: +44 (0) 161 742 3359
KEYWORD: UNITED KINGDOM EUROPE
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL
Copyright Business Wire 2018.
PUB: 10/01/2018 10:13 AM/DISC: 10/01/2018 10:13 AM